UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
|
|||
FORM 8-K/A
|
|||
CURRENT REPORT
|
|||
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
|||
Date of Report (Date of earliest event reported) March 26, 2014 | |||
RETROPHIN, INC.
|
|||
(Exact name of registrant as specified in its charter)
|
|||
Delaware
|
001-36257
|
27-4842691
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
777 Third Avenue, 22nd Floor, New York, NY
|
10017
|
||
(Address of principal executive offices)
|
(Zip Code)
|
||
Registrant’s telephone number, including area code (646) 837-5863
|
|||
|
|||
(Former name or former address, if changed since last report.)
|
|||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|||
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
10.1*
|
International Rights Purchase Agreement, dated as of March 26, 2014, by and between Manchester Pharmaceuticals LLC and Retrophin Therapeutics International, LLC.
|
10.2*
|
Membership Interest Purchase Agreement, dated as of March 26, 2014, by and among Retrophin, Inc., on the one hand, and Loring Creek Holdings LLC, Lloyd Glenn and Matthias Kurth, on the other hand.
|
10.3*
|
Secured Promissory Note, dated March 26, 2014, made by Retrophin, Inc. in favor of Loring Creek Holdings LLC, Lloyd Glenn and Matthias Kurth.
|
10.4*
|
Membership Interest Pledge Agreement, dated as of March 26, 2014, by and between Retrophin, Inc., on the one hand, and Loring Creek Holdings LLC, Lloyd Glenn and Matthias Kurth, on the other hand.
|
10.5*
|
Security Agreement, dated as of March 26, 2014, by and between Manchester Pharmaceuticals LLC, on the one hand, and Loring Creek Holdings LLC, Lloyd Glenn and Matthias Kurth, on the other hand.
|
99.1*
|
Press Release, dated March 27, 2014
|
99.2**
|
Audited financial statements of Manchester Pharmaceuticals LLC.
|
99.3
|
Unaudited pro forma combined condensed statement of operations for the year ended, December 31, 2013.
|
RETROPHIN, INC.
|
|||
Date: June 11, 2014 |
By:
|
/s/ Marc Panoff | |
Name: Marc Panoff
Title: Chief Financial Officer
|
|||
Manchester
Pharmaceuticals
|
Proforma Adjustment
|
Proforma
|
||||||||||||||
LLC |
Retrophin, Inc.
|
ref
|
Combined | |||||||||||||
Net product sales
|
$ | 4,393,822 | $ | - | $ | 4,393,822 | ||||||||||
Operating expenses:
|
||||||||||||||||
Cost of goods sold
|
438,898 | - | 438,898 | |||||||||||||
Research and development
|
100,000 | 7,084,009 | 7,184,009 | |||||||||||||
Selling, general and administrative
|
397,577 | 16,888,064 |
(a)
|
4,675,929 | 21,961,570 | |||||||||||
Total operating expenses
|
936,475 | 23,972,073 | 29,584,477 | |||||||||||||
Operating income (loss)
|
3,457,347 | (23,972,073 | ) | (25,190,655 | ) | |||||||||||
Other income (expenses):
|
||||||||||||||||
Interest income (expense), net
|
57 | (50,217 | ) |
(b)
|
(1,717,028 | ) | (1,767,188 | ) | ||||||||
Realized gain on sale of marketable securities, net
|
- | 374,482 | 374,482 | |||||||||||||
Change in fair value of derivative instruments
|
- | (10,099,926 | ) | (10,099,926 | ) | |||||||||||
Total other income (expense), net
|
57 | (9,775,661 | ) | (11,492,632 | ) | |||||||||||
Income (loss) before provision for income taxes
|
3,457,404 | (33,747,734 | ) | (36,683,287 | ) | |||||||||||
Income tax expense
|
- | (75,775 | ) | (75,775 | ) | |||||||||||
Net income (loss)
|
$ | 3,457,404 | $ | (33,823,509 | ) | $ | (36,759,062 | ) | ||||||||
Net loss per common share, basic and diluted
|
$ | - | $ | (2.38 | ) | $ | (2.08 | ) | ||||||||
Weighted average common shares outstanding, basic and diluted
|
- | 14,205,264 |
(c)
|
3,429,412 | 17,634,676 |
Amount
|
||||
Cash paid upon consummation, net
|
$ | 29,150,000 | ||
Secured promissory note
|
31,282,972 | |||
Fair value of contingent consideration
|
12,800,000 | |||
Total purchase price
|
$ | 73,232,972 | ||
Prepaid expenses
|
115,482 | |||
Inventory
|
350,030 | |||
Product rights
|
71,372,000 | |||
Trade names
|
175,000 | |||
Customer relationship
|
403,000 | |||
Goodwill
|
1,036,160 | |||
Other asset
|
1,522,063 | |||
Accounts payable and accrued expenses
|
(218,700 | ) | ||
Other liability
|
(1,522,063 | ) | ||
Total allocation of purchase price consideration
|
$ | 73,232,972 |
|
(a)
|
To reflect the incremental amortization based on the preliminary fair values of the intangible assets acquired. Retrophin engaged a third party valuation specialist to assist management. Based on the preliminary assessment, the acquired intangible asset categories, fair value and average amortization periods are as follows:
|
Fair Value
|
Average Amortization Method/Period
|
Estimated Annual Amortization Expense
|
||||||||
Product Rights
|
$ | 71,372,000 |
Straight Line
|
$ | 4,460,750 | |||||
Customer Relationships
|
403,000 |
Straight Line
|
40,179 | |||||||
Trade Name
|
175,000 |
Straight Line
|
175,000 | |||||||
Goodwill
|
1,036,160 |
Indefinite
|
- | |||||||
Total
|
$ | 72,986,160 | $ | 4,675,929 |
|
(b)
|
To reflect the imputed interest expense on the $33 million non-interest bearing note using a discount rate of 11.07%. The discount rate is estimated based on current borrowing rates available to the Company. The rate is determined using the current 1 Year LIBOR Rate of 0.53% plus 10.54%.
|
|
(c)
|
To reflect shares issued in Retrophin Inc.'s 2014 capital raise allocated to cash consideration paid upon consummation of acquisition. On January 9, 2014, the Company raised $40 million and issued 4,705,882 shares of common stock.
|